These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 23715301)
1. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. Salama JK; Hodgson L; Pang H; Urbanic JJ; Blackstock AW; Schild SE; Crawford J; Bogart JA; Vokes EE; J Thorac Oncol; 2013 Aug; 8(8):1043-9. PubMed ID: 23715301 [TBL] [Abstract][Full Text] [Related]
2. Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. Salama JK; Pang H; Bogart JA; Blackstock AW; Urbanic JJ; Hogson L; Crawford J; Vokes EE Lung Cancer; 2013 Dec; 82(3):436-40. PubMed ID: 24396884 [TBL] [Abstract][Full Text] [Related]
3. Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer. Zhang J; Fan M; Liu D; Zhao KL; Wu KL; Zhao WX; Zhu ZF; Fu XL Radiat Oncol; 2017 Mar; 12(1):51. PubMed ID: 28283034 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy. Winther-Larsen A; Hoffmann L; Moeller DS; Khalil AA; Knap MM Acta Oncol; 2015; 54(9):1574-81. PubMed ID: 26203924 [TBL] [Abstract][Full Text] [Related]
5. Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial. Salem A; Mistry H; Hatton M; Locke I; Monnet I; Blackhall F; Faivre-Finn C JAMA Oncol; 2019 Mar; 5(3):e185335. PubMed ID: 30520977 [TBL] [Abstract][Full Text] [Related]
6. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer]. You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970 [TBL] [Abstract][Full Text] [Related]
7. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342 [TBL] [Abstract][Full Text] [Related]
8. Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. Faivre-Finn C; Falk S; Ashcroft L; Bewley M; Lorigan P; Wilson E; Groom N; Snee M; Fournel P; Cardenal F; Bezjak A; Blackhall F BMJ Open; 2016 Jan; 6(1):e009849. PubMed ID: 26792218 [TBL] [Abstract][Full Text] [Related]
9. Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). Salama JK; Gu L; Wang X; Pang HH; Bogart JA; Crawford J; Schild SE; Vokes EE; Ready NE J Thorac Oncol; 2016 Mar; 11(3):361-9. PubMed ID: 26723241 [TBL] [Abstract][Full Text] [Related]
10. Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I to III small cell lung cancer. Reymen B; Van Loon J; van Baardwijk A; Wanders R; Borger J; Dingemans AM; Bootsma G; Pitz C; Lunde R; Geraedts W; Lambin P; De Ruysscher D Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1319-24. PubMed ID: 23200174 [TBL] [Abstract][Full Text] [Related]
11. High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. Yu J; Jiang L; Zhao L; Yang X; Wang X; Yang D; Zhuo M; Chen H; Huang W; Zhu Z; Zhang M; Song Y; Li Q; Ma Z; Wang Q; Qu Y; Yu R; Yu H; Zhao J; Shi A; Lancet Respir Med; 2024 Oct; 12(10):799-809. PubMed ID: 39146944 [TBL] [Abstract][Full Text] [Related]
12. Comparison of survival outcomes among standard radiotherapy regimens in limited-stage small cell lung cancer patients receiving concurrent chemoradiation. Rutter CE; Park HS; Corso CD; Yeboa DN; Mancini BR; Lester-Coll NH; Kim AW; Decker RH Lung Cancer; 2015 Nov; 90(2):243-8. PubMed ID: 26277031 [TBL] [Abstract][Full Text] [Related]
13. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. Stinchcombe TE; Fan W; Schild SE; Vokes EE; Bogart J; Le QT; Thomas CR; Edelman MJ; Horn L; Komaki R; Cohen HJ; Kishor Ganti A; Pang H; Wang X Cancer; 2019 Feb; 125(3):382-390. PubMed ID: 30343497 [TBL] [Abstract][Full Text] [Related]
14. Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized Trial. Qiu B; Li Q; Liu J; Huang Y; Pang Q; Zhu Z; Yang X; Wang B; Chen L; Fang J; Lin M; Jiang X; Guo S; Guo J; Wang D; Liu F; Chu C; Huang X; Xie C; Liu H Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):424-435. PubMed ID: 33992717 [TBL] [Abstract][Full Text] [Related]
15. Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Watkins JM; Fortney JA; Wahlquist AE; Shirai K; Garrett-Mayer E; Aguero EG; Sherman CA; Turrisi AT; Sharma AK Jpn J Radiol; 2010 Jun; 28(5):340-8. PubMed ID: 20585921 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239. Komaki R; Paulus R; Ettinger DS; Videtic GM; Bradley JD; Glisson BS; Langer CJ; Sause WT; Curran WJ; Choy H Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e531-6. PubMed ID: 22560543 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206. Kelley MJ; Bogart JA; Hodgson LD; Ansari RH; Atkins JN; Pang H; Green MR; Vokes EE J Thorac Oncol; 2013 Jan; 8(1):102-8. PubMed ID: 23196276 [TBL] [Abstract][Full Text] [Related]
18. Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis. Suzuki R; Wei X; Allen PK; Welsh JW; Cox JD; Komaki R; Lin SH Clin Lung Cancer; 2018 Nov; 19(6):e885-e891. PubMed ID: 30197263 [TBL] [Abstract][Full Text] [Related]
19. Effect of Thoracic Radiotherapy Timing and Fractionation on Survival in Nonmetastatic Small Cell Lung Carcinoma. Wong AT; Rineer J; Schwartz D; Becker D; Safdieh J; Osborn V; Schreiber D Clin Lung Cancer; 2017 Mar; 18(2):207-212. PubMed ID: 27686970 [TBL] [Abstract][Full Text] [Related]